The U.K.'s ReNeuron Group has raised £4.7 million ($7.3 million), before expenses, from existing and new institutional investors. The money will support the company for the next 12 months and be directed towards the Phase I trial of the company's ReN001 stem cell therapy for disabled stroke patients. It will also fund late pre-clinical testing of the company's ReN009 therapy for peripheral arterial disease. ReNeuron release